Somerset, N.J. & INTERPHEX, NYC, NY – April 26, 2016 — Catalent Pharma Solutions (Booth 1546), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, consumer health and animal health products, today announced that it has won the ‘Editor’s Choice’ category at the annual INTERPHEX Awards, for its OptiForm® Solution Suite platform.
OptiForm Solution Suite is an integrated, fixed price service, designed to efficiently and rapidly help solve complex bioavailability challenges for early stage molecules, using a unique toolkit of bioavailability enhancing technologies, including comprehensive molecule characterization and unique salt screening assessment combined with parallel processing up to four superior formulation technologies. OptiForm Solution Suite matches the best formulation technologies to the molecule, and utilizes an accelerated parallel screening and development approach, based on rigorous science and best-in-class scientific expertise, in just 12 weeks.
“In the early stages of drug development, it is vital to select a suitable formulation so that preclinical studies can be initiated quickly reaching satisfactory exposure,” commented Julien Meissonnier, Vice President, Science & Technology. “The combination of a wide array of advanced formulation technology options, and rapid screening and selection techniques available through the OptiForm Solution Suite can help overcome these challenges.”
Catalent’s OptiForm Solution Suite platform was presented at the INTERPHEX opening ceremony, on Tuesday, April 26th. The convention is currently taking place at The Javits Center, New York City, and runs until Thursday 28th April.
For further information or to arrange a meeting with a member of the executive team during the show, please contact Richard Kerns at email@example.com .
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics consumer health and animal health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 8,700 people, including over 1,000 scientists, at 31 facilities across 5 continents, and in fiscal 2015 generated more than $1.8 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit www.catalent.com